

NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

HEALTH TECHNOLOGY APPRAISAL PROGRAMME

Equality impact assessment – Guidance development

Sparsentan for treating primary IgA nephropathy

The impact on equality has been assessed during this appraisal according to the principles of the NICE equality scheme.

Consultation

- | | |
|-----------------|----------------------------------------------------------------------------------------------------------------------------|
| 1. | Have the potential equality issues identified during the scoping process been addressed by the committee, and, if so, how? |
| None identified | |

- | | |
|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| 2. | Have any other potential equality issues been raised in the submissions, expert statements or academic report, and, if so, how has the committee addressed these? |
| The committee considered that IgAN disproportionately affects certain ethnic groups, particularly people of Asian and Black ethnicity. The committee recognised that access to renal transplantation is often more challenging for these groups, with longer waiting times for suitable donor matches, which may result in prolonged dependence on dialysis. Committee were aware of the importance of slowing progression and delaying or reducing the need dialysis. The committee have not seen cost effectiveness results using all of its preferred assumptions and have requested to see additional analyses to address uncertainties in the evidence. | |

- | | |
|-----------------|-------------------------------------------------------------------------------------------------------------------------------|
| 3. | Have any other potential equality issues been identified by the committee, and, if so, how has the committee addressed these? |
| None identified | |

4.	Do the preliminary recommendations make it more difficult in practice for a specific group to access the technology compared with other groups? If so, what are the barriers to, or difficulties with, access for the specific group?
No	
5.	Is there potential for the preliminary recommendations to have an adverse impact on people with disabilities because of something that is a consequence of the disability?
No	
6.	Are there any recommendations or explanations that the committee could make to remove or alleviate barriers to, or difficulties with, access identified in questions 4 or 5, or otherwise fulfil NICE's obligations to promote equality?
No	
7.	Have the committee's considerations of equality issues been described in the draft guidance, and, if so, where?
Section 3.14	

Approved by Associate Director: Lorna Dunning

Date: 20/02/25